>>Encysive Expects to Submit Revised Response to Thelin Approvable Letter Within Several Days
Thursday December 14, 8:35 am ET
Conference Call Scheduled for Today At 9:00 a.m. Eastern
HOUSTON, Dec. 14, 2006 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (NASDAQ:ENCY - News) announced today that the U.S. Food and Drug Administration (FDA) informed the Company that its response to the July 24, 2006 approvable letter for Thelin(tm) (sitaxsentan sodium) 100 mg tablets is not considered to be complete. The FDA has requested that the Company provide information in a certain tabular format. The Company expects to provide the requested information within several days, and is hopeful that this information will resolve any remaining questions. Based on the straight-forward nature of the request, Encysive will ask the FDA to review the new tables expeditiously.
Conference Call Information
Encysive Pharmaceuticals will host a conference call today at 9:00 a.m. ET. You may access the call either through the call-in number below or through the audio webcast. Please dial in 15 minutes prior to the start time to allow for call processing. The access number for the call is:
Number: (612) 288-0340
Passcode: Encysive Pharmaceuticals
This call is being webcast and can be accessed via Encysive's web site at encysive.com.
A replay of the webcast will be available on the Company's web site through January 15, 2007. Additionally, a replay of the call will be available from Thursday, December 14, 2006, at 11:30 a.m. ET until Monday, December 18, 2006, at 11:59 p.m. ET. The call replay can be accessed by calling:
Number: (320) 365-3844
Access Code: 853968<<
snip
If they just need to fix table formatting, this shouldn't slow them down much. I might even add on the weakness. I need to listen to CC first, though that has never been illuminating in the past.
Cheeers, Tuck |
